TGNA
48
5
STI
12
2
QCOM
57
2
GOOG
61
2
PNW
66
-3
COST
54
-3
FOX
37
6
MCO
75
-2
BSX
69
-2
NOV
45
3
SYK
59
-5
DHR
56
-4
LB
52
7
F
47
3
CCL
67
2
NAVI
57
2
MUR
49
4
SIG
60
2
ADI
59
2
BIIB
25
-10
TGNA
48
5
STI
12
2
QCOM
57
2
GOOG
61
2
PNW
66
-3
COST
54
-3
FOX
37
6
MCO
75
-2
BSX
69
-2
NOV
45
3
SYK
59
-5
DHR
56
-4
LB
52
7
F
47
3
CCL
67
2
NAVI
57
2
MUR
49
4
SIG
60
2
ADI
59
2
BIIB
25
-10
Financhill
Back

VYNE Therapeutics 10K Form

Sell
22

VYNE
VYNE Therapeutics

Last Price:
1.89
Seasonality Move:
-14.98%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2021-04-20 10K VYNE/VYNE Therapeutics Annual
2021-03-04 10K VYNE/VYNE Therapeutics Annual
2020-11-05 10Q VYNE/VYNE Therapeutics Quarterly
2020-08-06 10Q VYNE/VYNE Therapeutics Quarterly
2020-05-11 10Q VYNE/VYNE Therapeutics Quarterly
2020-03-03 10K VYNE/VYNE Therapeutics Annual

Receive VYNE News And Ratings

See the #1 stock for the next 7 days that we like better than VYNE

VYNE Financial Statistics

Sales & Book Value

Annual Sales: $424K
Cash Flow: $-8.48M
Price / Cash Flow: 0
Annual Sales: $5.15
Price / Book: 0.36

Profitability

EPS (TTM): -2.81890
Net Income (TTM): $-28.43M
Gross Margin: $11.41M
Return on Equity: -51.55%
Return on Assets: -44.39%

VYNE Therapeutics Earnings Forecast

Key VYNE Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 2 years for VYNE is 1,225.56%.
  • The Selling, General & Administrative Expenses for VYNE have been equal to 3,154.48% of Gross Profit Margin.
  • The Research & Development expenses have been 3,845.99% of Revenue.
  • The Interest Expense is 0.00% of Operating Income.
  • The Net Earning history of VYNE is -6,710.38% of Total Revenues.
  • Per Share Earnings over the last 9 years have been positive in 4 years.

VYNE Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: VYNE
CUSIP: 92941V
Website: vynetherapeutics.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 7.13
Quick Ratio: 6.64

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

VYNE Technical Analysis vs Fundamental Analysis

Sell
22
VYNE Therapeutics (VYNE) is a Sell

Is VYNE Therapeutics a Buy or a Sell?

  • VYNE Therapeutics stock is rated a Sell
    The current VYNE Therapeutics [VYNE] share price is $1.83. The Score for VYNE is 22, which is 56% below its historic median score of 50, and infers higher risk than normal.